Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MNPR

Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MNPR
DateTimeSourceHeadlineSymbolCompany
01/06/202406:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
31/05/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
25/05/202406:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
24/05/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
24/05/202422:00GlobeNewswire Inc.Monopar Announces CFO SuccessionNASDAQ:MNPRMonopar Therapeutics Inc
09/05/202421:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
09/05/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
09/05/202421:00GlobeNewswire Inc.Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineNASDAQ:MNPRMonopar Therapeutics Inc
18/04/202422:00GlobeNewswire Inc.Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
16/04/202422:00GlobeNewswire Inc.Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsNASDAQ:MNPRMonopar Therapeutics Inc
10/04/202422:00GlobeNewswire Inc.Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsNASDAQ:MNPRMonopar Therapeutics Inc
28/03/202422:00GlobeNewswire Inc.Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
08/03/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
05/03/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
05/03/202423:00GlobeNewswire Inc.Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramNASDAQ:MNPRMonopar Therapeutics Inc
29/02/202405:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
27/02/202423:00GlobeNewswire Inc.Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialNASDAQ:MNPRMonopar Therapeutics Inc
27/02/202422:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
22/02/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
22/02/202423:00GlobeNewswire Inc.Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
21/02/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
21/02/202400:00GlobeNewswire Inc.Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
04/01/202411:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
04/01/202411:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
09/11/202323:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
09/11/202323:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
09/11/202323:00GlobeNewswire Inc.Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
01/11/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
01/11/202322:00GlobeNewswire Inc.Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
10/10/202322:00GlobeNewswire Inc.Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MNPR

Your Recent History

Delayed Upgrade Clock